Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sj&#xf6;gren&apos;s disease

Autoimmune Disease

A systematic review of clinical trial designs and outcome measures in Sjögren's disease randomized trials

J Rheumatol

Beydon M, Nguyen Y, Gordon R, Foulquier N, Bouillot C, Hammitt KM, Bowman SJ, Mariette X, Cornec D, McCoy SS, Seror R

doi: 10.3899/jrheum.2024-1012

Further Publications Rheumatology

FGL-1 Modulates Inter-Organ Communication by Controlling T Cell Homeostasis during the Onset of Sjögren's Disease

Arthritis Rheumatol

Otsuka K, Ushio A, Nagao R, Matsuzawa S, Arakaki R, Fukuta K, Mouri Y, Tsunematsu T, Ishimaru N

doi: 10.1002/art.43236

Further Publications Dermatology

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial

Lancet

Luckey A, Balasegaram M, Barbee LA, Batteiger TA, Broadhurst H, Cohen SE, Delany-Moretlwe S, de Vries HJC, Dionne JA, Gill K, Kenyon C, Kittiyaowamarn R, Lewis D, Mueller JP, Naicker V, O'Brien S, O'Donnell JP, Phanuphak N, Spooner E, Srinivasan S, Taylor SN, Unemo M, Zwane Z, Hook EW 3rd, Zoliflodacin Phase 3 Study Group

doi: 10.1016/S0140-6736(25)01953-1

Autoimmune Disease

A cross-sectional observational study of patients with sicca with salivary autoantibodies defines a potential new phenotype of Sjögren's disease

Ann Rheum Dis

Tsaliki M, Cavett J, Kurien BT, Bruxvoort C, Lewis VM, Ice JA, Dave D, Khosravani S, Grundahl K, Lessard CJ, Rasmussen A, Sivils KL, Farris AD, Koelsch KA, Scofield RH

doi: 10.1016/j.ard.2025.03.012

Immunotherapy

Development of salivary gland organoids derived from patient biopsies: a functional model of Sjögren's disease

Ann Rheum Dis

Meudec L, Goudarzi N, Silva-Saffar SE, Pascaud J, Jaulin F, Pascal Q, Lazure T, Bechara R, Mariette X, Nocturne G

doi: 10.1016/j.ard.2025.04.020

Rheumatoid Arthritis

Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

Arthritis Rheumatol

Liu J, Li Y, Fu K, Wu C, Schafer P, Connolly SE, Catlett IM, Maldonado MA, Wong R, Emery P, Tanaka Y, Bykerk VP, Bingham CO, Huizinga TWJ, Fleischmann R

doi: 10.1002/art.70106

Rheumatoid Arthritis

Clinical and molecular data to predict flares in DMARD optimization in rheumatoid arthritis: a randomised, controlled, open-label, non-inferiority trial

Rheumatology (Oxford)

Blanco FJ, Galindo L, Acasuso B, Balboa-Barreiro V, Cañete JD, Fernández-Gutiérrez B, González-Álvaro I, Álvarez JLP, Bejerano-Herrería C, Silva-Díaz M, Rego-Perez I, Lourido L, Ruiz-Romero C, Uriarte-Ecenarro M, García-Vicuña R, Cuervo A, Ramírez J, Celis R, Rodríguez-Rodríguez L, Abasolo Alcázar L, Nuñez DF, Martín-López M, Toro-Santos FJ, Oreiro N

doi: 10.1093/rheumatology/keag050

Rheumatoid Arthritis

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial

Lancet Rheumatol

Cope AP, Jasenecova M, Vasconcelos JC, Qureshi S, van Schie KA, Filer A, Raza K, D'Agostino MA, McInnes IB, Siebert S, Isaacs JD, Pratt AG, Fisher BA, Buckley CD, Emery P, Mankia K, Ho P, Buch MH, Ciurtin C, van Schaardenburg D, Huizinga TWJ, Toes REM, Georgiou E, Kelly J, Murphy C, Prevost AT, ALTO Study Investigators

doi: 10.1016/S2665-9913(25)00371-6

Melanoma and Skin Cancer

Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in the treatment of Bowen's disease: long-term results of a multicenter randomized controlled trial

J Am Acad Dermatol

Moermans MMG, Ahmady S, Nelemans PJ, Arits AHMM, Kessels JPHM, van Pelt HPA, Kelleners-Smeets NWJ, Mosterd K

doi: 10.1016/j.jaad.2025.12.034

Dermatology · Immunology · Rheumatology

Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren's disease

Related content

A systematic review of clinical trial designs and outcome measures in Sjögren's disease randomized trials

FGL-1 Modulates Inter-Organ Communication by Controlling T Cell Homeostasis during the Onset of Sjögren's Disease

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial

A cross-sectional observational study of patients with sicca with salivary autoantibodies defines a potential new phenotype of Sjögren's disease

Development of salivary gland organoids derived from patient biopsies: a functional model of Sjögren's disease

Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

Clinical and molecular data to predict flares in DMARD optimization in rheumatoid arthritis: a randomised, controlled, open-label, non-inferiority trial

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial

Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in the treatment of Bowen's disease: long-term results of a multicenter randomized controlled trial